---
title: "InMed shareholders back Mentari merger with cash lasting only into mid-November"
url: "https://aibio.space/news/inmed-shareholders-back-mentari-merger-cash-lasting-only-mid-november/"
event_date: "2026-11-03"
date_published: "2026-11-05"
description: "InMed held $1.1 million at September 30, had negative equity of $1.2 million and faces a March 15, 2027 Nasdaq deadline. Shareholders approved the merger proposals on November 4, and the company is now Mentari Therapeutics after a 1-for-10 consolidation."
---

# InMed shareholders back Mentari merger with cash lasting only into mid-November

InMed Pharmaceuticals Inc. (Nasdaq: INM) told investors on November 3, 2026, that cash and cash equivalents had fallen to $1,094,488 at September 30, enough by its own forecast to fund planned spending only into mid-November, and that shareholders' equity had turned negative. President and CEO Eric A. Adams put the merger with privately held Mentari Therapeutics to a shareholder vote the next day, and shareholders approved the proposals needed for it on November 4. The company's future as a listed company now rests on the deal closing and on Mentari's private placements of approximately US$490 million in expected aggregate gross proceeds. Until then, InMed's own balance sheet shows liabilities larger than its assets. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm) [November 5 8-K](https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/d173223d8k.htm)

## Cash, payables and the Nasdaq letter

Cash fell from $2,194,413 at June 30. Short-term investments were $40,331. Total liabilities were $2,505,258 against total assets of $1,305,862, leaving a shareholders' deficit of $1,199,396, compared with positive equity of $1,075,007 at June 30. Operating activities used $1,142,342 in the quarter, while accounts payable and accrued liabilities rose to $2,493,903 from $1,843,327. In our reading, part of the quarter's costs went unpaid rather than coming out of cash. The company says its cash lasts into mid-November depending on the level and timing of spending and on when the merger completes. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

On September 16, 2026, the Listing Qualifications Department of The Nasdaq Stock Market LLC told InMed that the $1,075,007 of shareholders' equity in its annual report for the year ended June 30, 2026 was below the $2.5 million minimum under Nasdaq Listing Rule 5550(b)(1). InMed filed a compliance plan on October 30, and the company says Nasdaq accepted it and set a March 15, 2027 deadline. Equity at September 30 was lower than the figure that triggered the letter. InMed expects the merger and the pre-closing financing to restore compliance, and warns there is no assurance it will regain compliance within any extension period. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

## The quarter's losses

Net loss for the three months ended September 30 was $2,330,778, against $1,726,899 a year earlier. The loss from continuing operations was $1,995,012, and discontinued operations lost $335,766. Research and development spending fell to $206,015 from $575,458, which the company attributes to reduced activity during the pending merger. General and administrative expenses rose to $1,804,625 from $1,239,058, nearly nine times research spending. The accumulated deficit reached $132,561,184. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

## What the vote approved

At the November 4 annual general and special meeting, 3,630,088 of the 5,493,735 common shares entitled to vote were represented. Shareholders approved the share issuance and change of control under Nasdaq Listing Rules 5635(a) and 5635(b) by 2,615,030 votes to 13,420. They also approved the return of capital, the redomestication from British Columbia to Nevada, a new stock incentive plan, an employee stock purchase plan and, on an advisory basis, merger-related pay for named executive officers. The redomestication drew 240,296 votes against and the stock plan 245,657. [November 5 8-K](https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/d173223d8k.htm)

The same day the company changed its name to Mentari Therapeutics, Inc. and consolidated its shares 1-for-10, cutting the count from 5,493,735 to approximately 549,374. Post-consolidation trading under INM was expected to start on November 5. The board also created 4,013 Series A Non-Voting Preferred Shares, each convertible into 1,000 common shares, subject to a 19.99% ownership limit. After closing, the combined company is expected to seek to trade on the Nasdaq Capital Market under the symbol MTRI, subject to Nasdaq approval, and the release says closing is expected in the fourth quarter of calendar 2026. [November 5 8-K](https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/d173223d8k.htm) [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

The release says Mentari's financing is expected to support operations into 2029, including through Phase 2a readouts for both of its lead PACAP-targeted programs. Those are projections about a private company, and the readouts are still ahead. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

## The legacy drugs and the CVRs

InMed says it held a pre-IND meeting with the FDA during the quarter and reached alignment on next steps for INM-901 in Alzheimer's disease. The release does not say what was agreed, and the company is looking to divest or license INM-901, INM-089 for dry age-related macular degeneration and INM-755 for dermatological indications rather than develop them itself. Holders of record at the close of business on November 5, 2026 are expected to receive one contingent value right per post-consolidation share, tied to any future monetization of those assets. InMed says there is no assurance any asset deal will be completed or any CVR payment made. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm) [November 5 8-K](https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/d173223d8k.htm)

The next filings should show when the merger closes, whether the Mentari money arrives before InMed's cash runs out, and whether the combined company meets Nasdaq's equity requirement by March 15, 2027. [Release](https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1728328/000106299326005723/exhibit99-1.htm
- https://www.sec.gov/Archives/edgar/data/1728328/000119312526448367/d173223d8k.htm
